Optimizing the Leveraging of Real-World Data to Improve the Development and Use of Medicines

被引:41
作者
Berger, Marc L. [1 ]
Lipset, Craig [1 ]
Gutteridge, Alex [1 ]
Axelsen, Kirsten [1 ]
Subedi, Prasun [1 ]
Madigan, David [2 ]
机构
[1] Pfizer Inc, New York, NY USA
[2] Columbia Univ, New York, NY USA
基金
美国国家科学基金会;
关键词
big data; data access; health research; health policy; real-world data;
D O I
10.1016/j.jval.2014.10.009
中图分类号
F [经济];
学科分类号
02 ;
摘要
Health research, including health outcomes and comparative effectiveness research, is on the cusp of a golden era of access to digitized real world data, catalyzed by the adoption of electronic health records and the integration of clinical and biological information with other data. This era promises more robust insights into what works in health care. Several barriers, however, will need to be addressed if the full potential of these new data are fully realized; these will involve both policy solutions and stakeholder cooperation. Although a number of these issues have been widely discussed, we focus on the one we believe is the most important the facilitation of greater openness among public and private stakeholders to collaboration, connecting information and data sharing, with the goal of making robust and complete data accessible to all researchers. In this way, we can better understand the consequences of health care delivery, improve the effectiveness and efficiency of health care systems, and develop advancements in health technologies. Early real-world data initiatives illustrate both potential and the need for future progress, as well as the essential role of collaboration and data sharing. Health policies critical to progress will include those that promote open source data standards, expand access to the data, increase data capture and connectivity, and facilitate communication of findings. Copyright (C) 2015, international Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.
引用
收藏
页码:127 / 130
页数:4
相关论文
共 12 条
[1]   Evaluating re-identification risks with respect to the HIPAA privacy rule [J].
Benitez, Kathleen ;
Malin, Bradley .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2010, 17 (02) :169-177
[2]  
Berger ML, 2014, J COMP EFFECT RES, V3, P167, DOI [10.2217/cer.14.2, 10.2217/CER.14.2]
[3]   Lithium delays progression of amyotrophic lateral sclerosis [J].
Fornai, Francesco ;
Longone, Patrizia ;
Cafaro, Luisa ;
Kastsiuchenka, Olga ;
Ferrucci, Michela ;
Manca, Maria Laura ;
Lazzeri, Gloria ;
Spalloni, Alicia ;
Bellio, Natascia ;
Lenzi, Paola ;
Modugno, Nicola ;
Siciliano, Gabriele ;
Isicloro, Ciro ;
Murri, Luigi ;
Ruggieri, Stefano ;
Paparelli, Antonio .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (06) :2052-2057
[4]   Efficient storage of high throughput DNA sequencing data using reference-based compression [J].
Fritz, Markus Hsi-Yang ;
Leinonen, Rasko ;
Cochrane, Guy ;
Birney, Ewan .
GENOME RESEARCH, 2011, 21 (05) :734-740
[5]   Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report [J].
Garrison, Louis P., Jr. ;
Neumann, Peter J. ;
Erickson, Pennifer ;
Marshall, Deborah ;
Mullins, Daniel .
VALUE IN HEALTH, 2007, 10 (05) :326-335
[6]   A Comparison of the Empirical Performance of Methods for a Risk Identification System [J].
Ryan, Patrick B. ;
Stang, Paul E. ;
Overhage, J. Marc ;
Suchard, Marc A. ;
Hartzema, Abraham G. ;
DuMouchel, William ;
Reich, Christian G. ;
Schuemie, Martijn J. ;
Madigan, David .
DRUG SAFETY, 2013, 36 :S143-S158
[7]  
Salford Royal NHS Trust, GROUNDBR STUD LAUNCH
[8]   Interpreting observational studies: why empirical calibration is needed to correct p-values [J].
Schuemie, Martijn J. ;
Ryan, Patrick B. ;
DuMouchel, William ;
Suchard, Marc A. ;
Madigan, David .
STATISTICS IN MEDICINE, 2014, 33 (02) :209-218
[9]  
U.S. Department of Health and Human Services, 2002, FED REG, V45 CFR
[10]  
Walter L, 2013, CLIN MED RES, V11, P148